Pharmaceutical Companies in Switzerland

Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression in multiple disease areas by selective inhibition of transcription factors in the cell nucleus. The lead compound CB-103 has advanced to Phase 2 treating patients with multi-drug resistant cancers. Further, Cellestia is advancing a rich R&D pipeline of novel transcription factor inhibitors, in oncology, auto-immune and inflammatory disorders, having achieved animal in-vivo proof of concept for several new targets. Cellestia was founded in 2014 as a spin-off from EPFL, Lausanne, Switzerland and is headquartered in Basel, Switzerland.

Our mission is to create a comprehensive, patient-centric ecosystem that empowers individuals and healthcare professionals alike through a unique digital health platform to bring more quality of life for everyone.

Abionic, an in vitro diagnostics (IVD) company, was founded in 2010 as a spin-off from the Swiss Federal Institute of Technology of Lausanne (EPFL). Abionic is aiming to make a difference in patient care through the cutting-edge nanofluidic technology based ultra-rapid diagnostic platform, helping healthcare professionals to make clinical decisions at the point of care.

BC Platforms is a global leader in building data networks for the life sciences industry and provides versatile technology platforms for personalised medicine, accelerating the translation of innovations into clinical practice. We convert complex biological information collected in the healthcare setting into actionable insights. With our innovative technology we are creating a patient centric infinity loop between the life sciences and healthcare sectors. Data we generate, harmonise, and manage, from diverse biobanks and healthcare institutions, is made accessible for pharmaceutical and biotech companies to enhance their core strengths in research and development. In parallel, we enable stratification of patients towards targeted therapies, delivering on the promise of more personalized healthcare. Our high performing genomic data discovery and analytics platform enables flexible data integration, secure analysis, and interpretation of molecular and clinical information. We have developed a Global Data Partner Network, BCRQUEST.com, which allows access to high-quality real-world data. This rapidly growing network has a footprint across many sites, including networks of major hospitals, covering 20 countries in five continents, providing standard of care data for over 23 million patients. Our platforms seamlessly facilitate access to highly enriched data for pharmaceutical research and development. Founded in 1997 from a MIT Whitehead project spinoff, we have a strong scientific heritage underpinned by over 25 years of working in close collaboration with a network of leading researchers, developers, and industry partners. We have global operations with our headquarters in Zurich, Switzerland, R&D in Espoo, Finland, and Singapore, as well as a presence in London and Boston. For more information, please visit www.bcplatforms.com.

Anjarium Biosciences AG is a genetic medicines company focused on creating and delivering a new generation of targeted gene therapies to patients. Anjarium’s versatile platform builds on novel therapeutic payloads and delivery technologies, with the aim to unlock the full potential of gene therapy.

Alentis Therapeutics, the Claudin-1 (CLDN1) company, is a clinical stage biotechnology company that focuses on developing first-in-class breakthrough treatments for CLDN1+ tumors and organ fibrosis. Alentis is pioneering a novel approach to modify and reverse the course of disease progression targeting CLDN1, a previously unexploited target that plays a key role in the pathology of tumors and fibrotic diseases across multiple organs. Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting CLDN1. Alentis’ portfolio of anti-CLDN1 monoclonal antibodies includes a novel class of anti-cancer therapies designed to reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is highly promising for drug development as many cancers use the TME to build barriers that shield against immune system attacks. Alentis’ lead oncology asset, ALE.C04, is the first potential treatment to target CLDN1 in solid tumors. In addition, Alentis’ pipeline includes first-in-class therapies designed to modify and reverse the course of advanced organ fibrosis. ALE.F02, which is currently in Phase 1 clinical trials, is designed to target pathological overexpression of CLDN1 outside of the tight junction to resolve and reverse organ fibrosis and is being investigated for the treatment of fibrotic disease in the kidney, lung, and liver. The company was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert MD at the University of Strasbourg and the French National Institute of Health (Inserm). Alentis is headquartered in Basel’s pharma-biotech hub in Switzerland with a subsidiary for R&D in Strasbourg, France. For more information, please visit us at www.alentis.ch or write to: info@alentis.ch

ImmunOs Therapeutics AG is developing the next generation of immunotherapies that have a role in the innate immune system for cancer and autoimmune diseases. The company is developing therapies that not only have direct anti-tumor effects but also remodel the tumor microenvironment to enhance the efficacy of existing immunotherapies. This portfolio of next generation, novel immunomodulatory proteins target diverse and key immunoregulatory receptors. Our lead program iosH2, now advancing to Phase 1 studies, is a multi-functional fusion protein that blocks specific LILRB (leukocyte immunoglobulin-like) receptors and thereby activates anti-tumor responses in multiple cancers with monotherapy and in combination with checkpoint inhibitors (CTLA-4, PD-1, PD-L1, CD47) and costimulatory agonists (e.g. 4-1BB).

Acino is a Swiss pharmaceutical company headquartered in Zurich, with a clear focus on high-growth markets. We deliver quality pharmaceuticals to promote affordable healthcare and leverage our high-quality pharmaceutical manufacturing capabilities and network to supply leading companies through contract manufacturing and out-licensing. For more information: www.acino.swiss *** By engaging with Acino on YouTube (or any other Acino social media channel), you are agreeing to our Social Media Community Guidelines. If you do not agree to them, do not engage with Acino on social media. Please read our detailed community guidelines carefully here: https://acino.swiss/acino_social_media_community_guidelines_may2022 ***

Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.

Actando is an innovative global learning organisation that empowers life sciences customers with skills and tools that drive business performance and accelerate overall organisational effectiveness. We’ve seen a lot of change occur in life sciences—and recognize that quickly adapting to change is not easy. Success in this industry requires specific knowledge and skills and we work hard to acquire and offer this expertise to our clients. Our team is made up of a focused group of experts that touch each aspect of life sciences—including sales, marketing and commercial excellence, along with the technological know-how to make it work. We know this world and its unique aspects and can help you adapt and succeed quickly. Our team is committed to creating environments of continuous learning, and we work hard to arm you with all the relevant data, insights, and recommendations to help your organization keep climbing. Our unique blended learning programmes, supported by ongoing assessment, implementation and decision-making data and tools, empower sales, marketing and commercial life sciences teams to effectively plan, execute and measure performance. The results are employees who can thrive in the midst of market change and companies who can stop playing catch up and start operating successfully in today’s fast-paced world.

Sintetica is a swiss pharmaceutical company established in 1921. We are fully committed to innovate therapies and drugs in anaesthesia, pain management, intensive care and neuromodulation.

KD Pharma Group | Creating Health Solutions The KD Pharma Group is a CDMO that develops products in the pharmaceutical and nutraceutical space. It is also the worldwide leading producer of API for Omega-3 pharmaceuticals and has built a similar market-leading position in Omega-3 nutraceuticals, formulation and encapsulation services, with over 500 employees and a presence in the UK, Norway, Germany, Switzerland and the US. The KD Pharma Group employs state-of-the-art technology which is protected by numerous patents.

MediFood was founded with the purpose of developing research-based, innovative clinical nutrition products. Using state-of-the-art technology MediFood produces high-quality “Foods for Special Medical Purposes” (FSMP). These are specially formulated medical foods that are processed and intended for the dietary management of diseases, disorders or medical conditions of individuals treated under medical supervision.

Demiurge pioneers high-accuracy MoA-based prediction of clinical trial outcomes. * Posts here are for information only without any warranty of any kind.

Genkyotex has become a wholly owned subsidiary of Calliditas and have been delisted from the Euronext stock exchanges. Genkyotex’s lead product candidate, setanaxib, is a first-in-class NOX inhibitor that targets NOX 1 and NOX 4, which are major drivers of fibrogenesis in multiple organs. In Q4 2021, Calliditas plans to initiate a 52-week, randomized, placebo-controlled, double-blind, trial with an adaptive phase 2b/3 design with setanaxib in 318 patients with primary biliary cholangitis (PBC). As previously announced in August 2021, Calliditas received FDA fast track designation for setanaxib in PBC. Calliditas will also initiate a Phase 2 proof-of-concept study in head and neck cancer in 2021, which will investigate the administration of setanaxib in conjunction with immunotherapy targeting cancer associated fibroblasts (CAFs). Follow @Calliditas Therapeutics for updates on future developments: https://www.linkedin.com/company/calliditas-therapeutics/

PeakData helps pharmaceutical companies learn more about their customers through our agile targeting and segmentation SaaS platform. PeakData is used by more than half of the top 20 Pharmaceuticals and engages 50+ staff in our offices in the USA, Germany, UK, Poland, Netherlands, and Switzerland.

Alchem NicSelect is the world's leading nicotine manufacturer for the next generation nicotine delivery (NGND) and vaping industries, with a longstanding heritage. For over 75 years, we have been manufacturing high-quality active ingredients (API) for the world's major pharmaceutical, nutraceutical and cosmetic brands.

Ewopharma is the successor company to M.R. Leclerc & Co., founded in 1959. From the start, our focus has been on building bridges to the pharmaceutical markets of Central Eastern Europe. Much has changed in the region since 1959 – both economically and politically – and over this period we have gained an in-depth understanding of the markets and an esteemed standing there. While we started out purely as a marketing partner for pharmaceutical companies, we have since acquired and launched proprietary products. Our brand Revalid® – a product line for holistic hair care and hair loss treatment–was developed in 1992 in Switzerland. In 2011, we acquired Irish healthcare company Newport Pharmaceuticals Ltd. giving us full ownership of the antiviral drug Isoprinosine® in 2011.Overseen by our head office in Schaffhausen, Switzerland, we now channel our industry knowledge and experience into the successful placement of both Ewopharma and partner brands in our target markets. In 2004, we joined the RX-Alliance, a professional cooperation network of successful pharmaceutical companies active in selected European markets.